Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection

Pediatrics International

Volumn 55, Issue 6, 2013, Pages 714-721

  Yamamoto, Takehisa ^a   Ihashi, Mai ^a   Mizoguchi, Yoshimi ^a   Kaneno, Hiroshi ^a   Yamamoto, Katsusuke ^a   Inoue, Yutaka ^a   Kase, Tetsuo ^b   Okabe, Nobuhiko ^c   Shimotsuji, Tsunesuke ^a  

^a Minoh City Hospital   (Japan)

^b OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^c KAWASAKI CITY INSTITUTE FOR PUBLIC HEALTH   (Japan)

Author keywords

early therapy; estimated clinical severity; influenza A (H1N1) pdm 2009; mean covariance structure equation analysis; neuraminidase inhibitor

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 MICROGLOBULIN; CREATININE; HERBACEOUS AGENT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; OSELTAMIVIR; ZANAMIVIR; ENZYME INHIBITOR; SIALIDASE;

2009 H1N1 INFLUENZA; ARTICLE; BAYES THEOREM; BODY TEMPERATURE; BREATHING RATE; CHILD CARE; CYTOKINE STORM; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HERBAL MEDICINE; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PULSE RATE; TREATMENT DURATION; VITAL SIGN; ANTAGONISTS AND INHIBITORS; CHILD; EARLY INTERVENTION; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN;

CHILD; EARLY MEDICAL INTERVENTION; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR;

EID: 84890550891     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12154     Document Type: Article

References (26)

1. Sugaya N, Shinjoh M, Mitamura K, Takahashi T,. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: Analysis of 1000 hospitalized children. J. Infect. 2011; 63: 288-294.
2. Zarychanski R, Stuart TL, Kumar A, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182: 257-264.
3. Rodríguez A, Díaz E, Martín-Loeches I, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J. Antimicrob. Chemother. 2011; 66: 1140-1149.
4. Khandaker G, Zurynski Y, Lester-Smith D, et al. Clinical features, oseltamivir treatment and outcome in infants aged <12 months with laboratory-confirmed influenza A in 2009. Antivir. Ther. 2011; 16: 1005-1010.
5. Kawai N, Ikematsu H, Hirotsu N, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: A Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin. Infect. Dis. 2009; 49: 1828-1835.
6. Sugaya N,. Widespread use of neuraminidase inhibitors in Japan. J. Infect. Chemother. 2011; 17: 595-601.
7. Bentler PM, Stein JA,. Structural equation models in medical research. Stat. Methods Med. Res. 1992; 1: 159-181.
8. Genser B, Cooper PJ, Yazdanbakhsh M, Barreto ML, Rodrigues LC,. A guide to modern statistical analysis of immunological data. BMC Immunol. 2007; 8: 27.
9. Beran TN, Violato C,. Structural equation modeling in medical research: A primer. BMC Res. Notes 2010; 3: 267-12.
10. Cox CL, Hudson MM, Mertens A, et al. Medical screening participation in the childhood cancer survivor study. Arch. Intern. Med. 2009; 169: 454-462.
11. Yamamoto T, Mizoguchi Y, Kaneno H, et al. Serum immunoglobulin G subclass levels and estimated clinical severity caused by possible influenza A (H1N1) pdm 2009 infection. J. Infect. Chemother. 2013. doi: 10.1007/S10156-013-0570-4
12. Kubo T, Nishimura H,. Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children. Phytomedicine 2007; 14: 96-101.
13. Sakai E, Yamamoto T, Yamamoto K, et al. A case study of IgG3 deficiency regarding the severity of influenza H1N1 pdm 09. Pediatr. Int. 2012; 54: 758-761.
14. Nishimaki S, Sato M, An H, et al. Comparison of markers for fetal inflammatory response syndrome: Fetal blood interleukin-6 and neonatal urinary beta2-microglobulin. J. Obstet. Gynaecol. Res. 2009; 35: 472-476.
15. Bentler PM,. Comparative fit indices in structural equation models. Psychol. Bull. 1990; 107: 238-246.
16. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 1995; 57: 289-300.
17. Li IW, Hung IF, To KK, et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 2010; 137: 759-768.
18. Atkins CY, Patel A, Taylor TH Jr, et al. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg. Infect. Dis. 2011; 17: 1591-1598.
19. Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: A systematic review and meta-analysis in hospitalized patients. J. Infect. Dis. 2013; 207: 553-563.
20. Masiá M, Padilla S, Antequera P, et al. Predictors of pneumococcal co-infection for patients with pandemic (H1N1) 2009. Emerg. Infect. Dis. 2011; 17: 1475-1478.
21. Koon K, Sanders CM, Green J, et al. Co-detection of pandemic (H1N1) 2009 virus and other respiratory pathogens. Emerg. Infect. Dis. 2010; 16: 1976-1978.
22. Takeuchi M, Yasunaga H, Horiguchi H, Matsuda S,. Clinical features of infants hospitalized for 2009 pandemic influenza A (H1N1) in Japan: Analysis using a national hospital discharge database. Pediatr. Infect. Dis. J. 2012; 1: 368-372.
23. Viasus D, Paño-Pardo JR, Pachõn J, et al. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest 2011; 140: 1025-1032.
24. Okada T, Morozumi M, Matsubara K, et al. Characteristic findings of pediatric inpatients with pandemic (H1N1) 2009 virus infection among severe and non-severe illnesses. J. Infect. Chemother. 2011; 17: 238-245.
25. Yu X, Zhang X, Zhao B, et al. Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. PLoS ONE 2011; 6: e28680.
26. Meulenbroek AJ, Zeijlemaker WP,. IgG subclasses in disease. 3. In:, Nieuwenhuys ED, (ed). Human IgG Subclasses: Useful Diagnostic Markers for Immunocompetence. Sanquin (formerly CLB), Amsterdam, 1996.